Azithromycin treatment in children hospitalized with asthma: a retrospective cohort study

Lindsey C. Douglas, Jaeun Choi, Nora Esteban-Cruciani

Research output: Contribution to journalArticle

Abstract

Objective: Azithromycin has anti-inflammatory properties in the lungs and decreases the duration of asthma-like episodes in children. We sought to evaluate length of stay (LOS) and readmission rates of children receiving azithromycin therapy during hospitalization for acute asthma exacerbations. Methods: This was a retrospective cohort study at an urban, quaternary-care children's hospital including patients under 18 years old hospitalized for asthma, without concurrent infection, from 2002 to 2011. The primary predictor was azithromycin therapy administered within 48 hours of admission. The primary outcome was LOS and the secondary outcomes were 7, 30, and 90-day hospital readmission rates for asthma. Results: Azithromycin therapy was administered to 174 (3%) of 5335 unique patients admitted for asthma, without concurrent infection, over the 10-year period. The overall median LOS was 2.3 days [Interquartile range, 1.8–3.1] and 9% (480) were readmitted for asthma within 90 days of discharge. Azithromycin therapy was associated with a 20% (11 hour) longer LOS (adjusted beta coefficient for log-transformed LOS, 0.18; 95% Confidence Interval (CI): 0.11–0.26), less than the 29% (16 hour) difference determined a priori as clinically relevant. Azithromycin therapy was not associated with 90-day readmission for asthma (adjusted odds ratio, 0.89; 95% CI: 0.46–1.72]. The limited number of 7 and 30-day readmissions in the azithromycin treated group precluded adjusted analysis. Conclusions: Azithromycin therapy was not associated with a clinically relevant difference in hospital LOS or with readmission rates for children hospitalized with asthma. Prospective trials are needed to determine the clinical effects of azithromycin therapy in children with asthma.

Original languageEnglish (US)
JournalJournal of Asthma
DOIs
StatePublished - Jan 1 2019

Fingerprint

Azithromycin
Hospitalized Child
Cohort Studies
Asthma
Retrospective Studies
Length of Stay
Therapeutics
Confidence Intervals
Patient Readmission
Child Care
Infection
Hospitalization
Anti-Inflammatory Agents
Odds Ratio
Lung

Keywords

  • children
  • hospital medicine
  • length of stay
  • macrolides
  • readmission
  • retrospective cohort study

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Azithromycin treatment in children hospitalized with asthma : a retrospective cohort study. / Douglas, Lindsey C.; Choi, Jaeun; Esteban-Cruciani, Nora.

In: Journal of Asthma, 01.01.2019.

Research output: Contribution to journalArticle

@article{346b5fa5919b467889551d3ff426278f,
title = "Azithromycin treatment in children hospitalized with asthma: a retrospective cohort study",
abstract = "Objective: Azithromycin has anti-inflammatory properties in the lungs and decreases the duration of asthma-like episodes in children. We sought to evaluate length of stay (LOS) and readmission rates of children receiving azithromycin therapy during hospitalization for acute asthma exacerbations. Methods: This was a retrospective cohort study at an urban, quaternary-care children's hospital including patients under 18 years old hospitalized for asthma, without concurrent infection, from 2002 to 2011. The primary predictor was azithromycin therapy administered within 48 hours of admission. The primary outcome was LOS and the secondary outcomes were 7, 30, and 90-day hospital readmission rates for asthma. Results: Azithromycin therapy was administered to 174 (3{\%}) of 5335 unique patients admitted for asthma, without concurrent infection, over the 10-year period. The overall median LOS was 2.3 days [Interquartile range, 1.8–3.1] and 9{\%} (480) were readmitted for asthma within 90 days of discharge. Azithromycin therapy was associated with a 20{\%} (11 hour) longer LOS (adjusted beta coefficient for log-transformed LOS, 0.18; 95{\%} Confidence Interval (CI): 0.11–0.26), less than the 29{\%} (16 hour) difference determined a priori as clinically relevant. Azithromycin therapy was not associated with 90-day readmission for asthma (adjusted odds ratio, 0.89; 95{\%} CI: 0.46–1.72]. The limited number of 7 and 30-day readmissions in the azithromycin treated group precluded adjusted analysis. Conclusions: Azithromycin therapy was not associated with a clinically relevant difference in hospital LOS or with readmission rates for children hospitalized with asthma. Prospective trials are needed to determine the clinical effects of azithromycin therapy in children with asthma.",
keywords = "children, hospital medicine, length of stay, macrolides, readmission, retrospective cohort study",
author = "Douglas, {Lindsey C.} and Jaeun Choi and Nora Esteban-Cruciani",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/02770903.2019.1590590",
language = "English (US)",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Azithromycin treatment in children hospitalized with asthma

T2 - a retrospective cohort study

AU - Douglas, Lindsey C.

AU - Choi, Jaeun

AU - Esteban-Cruciani, Nora

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Azithromycin has anti-inflammatory properties in the lungs and decreases the duration of asthma-like episodes in children. We sought to evaluate length of stay (LOS) and readmission rates of children receiving azithromycin therapy during hospitalization for acute asthma exacerbations. Methods: This was a retrospective cohort study at an urban, quaternary-care children's hospital including patients under 18 years old hospitalized for asthma, without concurrent infection, from 2002 to 2011. The primary predictor was azithromycin therapy administered within 48 hours of admission. The primary outcome was LOS and the secondary outcomes were 7, 30, and 90-day hospital readmission rates for asthma. Results: Azithromycin therapy was administered to 174 (3%) of 5335 unique patients admitted for asthma, without concurrent infection, over the 10-year period. The overall median LOS was 2.3 days [Interquartile range, 1.8–3.1] and 9% (480) were readmitted for asthma within 90 days of discharge. Azithromycin therapy was associated with a 20% (11 hour) longer LOS (adjusted beta coefficient for log-transformed LOS, 0.18; 95% Confidence Interval (CI): 0.11–0.26), less than the 29% (16 hour) difference determined a priori as clinically relevant. Azithromycin therapy was not associated with 90-day readmission for asthma (adjusted odds ratio, 0.89; 95% CI: 0.46–1.72]. The limited number of 7 and 30-day readmissions in the azithromycin treated group precluded adjusted analysis. Conclusions: Azithromycin therapy was not associated with a clinically relevant difference in hospital LOS or with readmission rates for children hospitalized with asthma. Prospective trials are needed to determine the clinical effects of azithromycin therapy in children with asthma.

AB - Objective: Azithromycin has anti-inflammatory properties in the lungs and decreases the duration of asthma-like episodes in children. We sought to evaluate length of stay (LOS) and readmission rates of children receiving azithromycin therapy during hospitalization for acute asthma exacerbations. Methods: This was a retrospective cohort study at an urban, quaternary-care children's hospital including patients under 18 years old hospitalized for asthma, without concurrent infection, from 2002 to 2011. The primary predictor was azithromycin therapy administered within 48 hours of admission. The primary outcome was LOS and the secondary outcomes were 7, 30, and 90-day hospital readmission rates for asthma. Results: Azithromycin therapy was administered to 174 (3%) of 5335 unique patients admitted for asthma, without concurrent infection, over the 10-year period. The overall median LOS was 2.3 days [Interquartile range, 1.8–3.1] and 9% (480) were readmitted for asthma within 90 days of discharge. Azithromycin therapy was associated with a 20% (11 hour) longer LOS (adjusted beta coefficient for log-transformed LOS, 0.18; 95% Confidence Interval (CI): 0.11–0.26), less than the 29% (16 hour) difference determined a priori as clinically relevant. Azithromycin therapy was not associated with 90-day readmission for asthma (adjusted odds ratio, 0.89; 95% CI: 0.46–1.72]. The limited number of 7 and 30-day readmissions in the azithromycin treated group precluded adjusted analysis. Conclusions: Azithromycin therapy was not associated with a clinically relevant difference in hospital LOS or with readmission rates for children hospitalized with asthma. Prospective trials are needed to determine the clinical effects of azithromycin therapy in children with asthma.

KW - children

KW - hospital medicine

KW - length of stay

KW - macrolides

KW - readmission

KW - retrospective cohort study

UR - http://www.scopus.com/inward/record.url?scp=85063631209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063631209&partnerID=8YFLogxK

U2 - 10.1080/02770903.2019.1590590

DO - 10.1080/02770903.2019.1590590

M3 - Article

AN - SCOPUS:85063631209

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

ER -